{
    "clinical_study": {
        "@rank": "159645", 
        "arm_group": [
            {
                "arm_group_label": "Resectable Patients", 
                "arm_group_type": "Experimental", 
                "description": "Surgery with Intraoperative Radiation Therapy (IORT).  Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery"
            }, 
            {
                "arm_group_label": "Marginally Resectable Patients", 
                "arm_group_type": "Experimental", 
                "description": "2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy.  Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the ability of a combination of updated and approved modalities in the treatment\n      of first line pancreatic cancer patients to increase the time to Progression Free Survival"
        }, 
        "brief_title": "Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "For resectable patient; surgery with Intraoperative Radiation Therapy (IORT).  Radiation\n      Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within\n      12 weeks of surgery.\n\n      For marginally resectable patients; the patients will have 2-3 cycles of neoadjuvant\n      chemotherapy of FOLFIRINOX and then restaged, undergo surgery with IORT within 2-4 weeks\n      following chemotherapy.  Then radiation therapy starting within 6-8 weeks.  Followed by\n      FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven Exocrine Adenocarcinoma of the pancreas\n\n          -  Clinically resectable or marginally resectable disease\n\n          -  No prior radiation or chemotherapy for carcinoma of the pancreas\n\n          -  ECOG performance status of 0-1\n\n          -  Patients must be medically able to undergo surgical resection\n\n          -  Patients of child bearing potential must follow study specific precautions\n\n          -  Women that are lactating will not be excluded on the condition that they dispose\n             their breast milk.\n\n          -  Adequate hematologic and biochemical parameters.\n\n        Exclusion Criteria:\n\n          -  Prior treatment for pancreatic cancer.\n\n          -  Concurrent investigational treatments.\n\n          -  Unresectable pancreatic mass.\n\n          -  Neuroendocrine Histological pancreatic cancer\n\n          -  Distant Metastatic disease\n\n          -  Any condition that, in the option of the investigator, would compromise the well\n             being of the patient or anything that would prevent the patient from meeting or\n             performing study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01760694", 
            "org_study_id": "SRMC 12-08", 
            "secondary_id": "IORT Pancreatic"
        }, 
        "intervention": {
            "arm_group_label": [
                "Resectable Patients", 
                "Marginally Resectable Patients"
            ], 
            "intervention_name": "Multi-Modality; IORT, Surgery, Radiation, Chemotherapy", 
            "intervention_type": "Other", 
            "other_name": [
                "Intraoperative Radiation Therapy (IORT)", 
                "Chemotherapy: FOLFIRINOX, Oxaliplatin, Irinotecan, 5-FU, Leucovorin", 
                "Surgery: Resectable or Marginally Resectable"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pancreatic", 
            "Pancreas", 
            "Intraoperative Radiation Therapy", 
            "Chemotherapy"
        ], 
        "lastchanged_date": "January 23, 2013", 
        "link": {
            "description": "Facility website address", 
            "url": "http://cancercenter.com"
        }, 
        "location": {
            "contact": {
                "email": "jj.hale@ctca-hope.com", 
                "last_name": "JJ Hale, BS, CCRC, CCRP", 
                "phone": "918-286-5449"
            }, 
            "contact_backup": {
                "email": "michele.sumner@ctca-hope.com", 
                "last_name": "Michele Sumner, BS, CCRC", 
                "phone": "918-286-5450"
            }, 
            "facility": {
                "address": {
                    "city": "Tulsa", 
                    "country": "United States", 
                    "state": "Oklahoma", 
                    "zip": "74133"
                }, 
                "name": "Southwestern Regional Medical Center, Inc."
            }, 
            "investigator": {
                "last_name": "Theodore Pollock, DO", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer", 
        "overall_contact": {
            "email": "jj.hale@ctca-hope.com", 
            "last_name": "JJ Hale, BS, CCRC", 
            "phone": "918-286-5449"
        }, 
        "overall_official": {
            "affiliation": "Southwestern Regional Medical Center, Inc.", 
            "last_name": "Theodore Pollock, DO", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Interim analysis at specific time points.  Measure disease response by CT scans per standard of care or when clinically indicated.", 
            "measure": "Efficacy - Progression Free Survival", 
            "safety_issue": "Yes", 
            "time_frame": "2 years after last patient enrolled"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01760694"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Interim analysis at certain time points.  Measure disease response by CT scans per standard of care or when clinically indicated.  Collect adverse events and serious adverse events. Collect quality of life data.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "2 years after last patient enrolled"
        }, 
        "source": "Southwestern Regional Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Southwestern Regional Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}